Vividion Therapeutics Agrees to Sell to Bayer for up to $2 Billion

Brandon C on August 12, 2021

Cooley advised Vividion Therapeutics, a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics, on its agreement to sell to Bayer AG for a purchase price of $1.5 billion and up to $500 million in success-based milestone payments.

Disclaimer

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, Cooley SG LLP, Cooley HK or any other Cooley entity (collectively referred to as “Cooley”). By reviewing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice, and it is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep it confidential. This content may be considered Attorney Advertising and is subject to our legal notices. The views expressed on the blog do not constitute legal advice, and are the views of the authors only and not those of Cooley.

Legal notices & privacy policy

Categories

Tags

Archives

Vividion Therapeutics Agrees to Sell to Bayer for up to $2 Billion

Related